- NCIt
- C35427
Loading cancer entity…
Loading cancer entity…
Clinical trials
10 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04982900 | Treatment of EGFR-TKI for Residual Lesions of Multiple Synchronous Ground-glass Opacities(TERMGGO) | unknown | Phase 2 | 138 | Ruijin HospitalOTHER | 1 | Oct 5, 2021 | clinicaltrials |
| NCT04840758 | Stereotactic Ablation Radiotherapy Combined With Sintilimab in Early Inoperable Synchronous Multiple Primary Lung Cancer | unknown | Phase 1 / Phase 2 | 39 | The First Affiliated Hospital of Xiamen UniversityOTHER | 0 | Apr 12, 2021 |
| clinicaltrials |
| NCT04026841 | The Efficacy of PD-1 Antibody Sintilimab on Early-stage Multiple Primary Lung Cancer With Ground Glass Density. | unknown | Phase 2 | 36 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Aug 2, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Oct 5, 2021source: clinicaltrials